-
Dec 9, 2024 | 
nature.com | Nadia Harbeck |Eva Ciruelos |Roisin M. Connolly |Sally Baron-Hay |Giampaolo Bianchini |Hans Wildiers | +1 more
Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03261-7, published online 13 September 2024. In the version of this article initially published, members of the DESTINY-Breast12 study group were not included by the journal in the full text. In Table 1, under the “Prior CNS therapies n (%)” section, seven rows have been added, in addition to the original CNS radiotherapy, WBRT and SRS rows.
-
Nov 15, 2024 | 
onclive.com | Nancy Lin
CommentaryVideoNovember 15, 2024Author(s):Nancy U. Lin, MD, discusses the safety data from DESTINY-Breast12 with T-DXd for HER2+ advanced/metastatic breast cancer with or without brain metastases. Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Dana-Farber Cancer Institute, Susan F.
-
Nov 10, 2024 | 
journals.sagepub.com | Jayant Y. Gadrey |Sarah L. Sammons |Nancy Lin |Stacey Pan
IntroductionIn recent years, there have been significant strides toward developing effective therapeutic options for patients with metastatic breast cancer (MBC).
-
Oct 30, 2024 | 
nature.com | Johanna Klughammer |Daniel L. Abravanel |Timothy R. Blosser |Yury Goltsev |Chiara Caraccio |Nicole Cullen | +7 more
AbstractAlthough metastatic disease is the leading cause of cancer-related deaths, its tumor microenvironment remains poorly characterized due to technical and biospecimen limitations. In this study, we assembled a multi-modal spatial and cellular map of 67 tumor biopsies from 60 patients with metastatic breast cancer across diverse clinicopathological features and nine anatomic sites with detailed clinical annotations.
-
Oct 27, 2024 | 
curetoday.com | Nancy Lin |Allie Hershey
Megan English, RN, BSN, is an experienced oncology infusion nurse at Dana-Farber Cancer Institute. She has been incredibly devoted to the care of oncology patients. I work with her to care for patients with all stages of breast cancer. She is incredibly kind and compassionate with patients and has excellent clinical judgment. She is great with communication with patients, their families and with the larger oncology treatment team so that everyone is on the same page.
-
Oct 23, 2024 | 
nature.com | Alexandre Poirier |Anne-Marie N. Fortier |Nancy Lin |Morag Park |Michel Tremblay |Rinath Jeselsohn
AbstractRecurrent breast cancers often develop resistance to standard-of-care therapies. Identifying targetable factors contributing to cancer recurrence remains the rate-limiting step in improving long-term outcomes. In this study, we identify tumor cell-derived osteopontin as an autocrine and paracrine driver of tumor recurrence. Osteopontin promotes tumor cell proliferation, recruits macrophages, and synergizes with IL-4 to further polarize them into a pro-tumorigenic state.
-
Oct 22, 2024 | 
medscape.com | Kathy D. Miller |Nancy Lin
Authors and Disclosures Kathy D. Miller, MD Ballvé Lantero Professor, Department of Medicine, Division of Hematology and Oncology; Associate Director for Clinical Research, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IndianaDisclosure: Kathy D.
-
Oct 16, 2024 | 
onclive.com | Nancy Lin
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Dana-Farber Cancer Institute, Susan F.
-
Oct 2, 2024 | 
healio.com | Savannah Demko |Nancy Lin |Mindy Valcarcel
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In a video interview,Nancy Lin, MD, of Dana-Farber Cancer Institute, talked about an analysis of HERA trial data presented at ESMO Congress.
-
Oct 2, 2024 | 
healio.com | Savannah Demko |Nancy Lin |Mindy Valcarcel
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Nancy Lin, MD, from the department of medical oncology at Dana-Farber Cancer Institute, discussed exciting OS data from the KEYNOTE-522 study presented at ESMO Congress.
